Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases

Epidermal growth factor receptor tyrosine kinase inhibitors, gefitnib and erlotinib, are effective for advanced nonsmall-cell lung cancer with epidermal growth factor receptor gene mutation. However, interstitial lung disease induced by these drugs is sometimes fatal, and discontinuation of the medi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Arakawa, Nobuhito, Tsujita, Akihiro, Saito, Noriko, Ishikawa, Shigemi, Ohno, Shoji
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Blackwell Publishing Ltd 2013
Gaiak:
Case Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4184641/
https://ncbi.nlm.nih.gov/pubmed/25473530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rcr2.12
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak